When MobileODT launched its mobile colposcope, disinfectant company Tristel immediately felt a connection with its mission of making vulvar and cervical screening simpler, faster and more effective.
By harnessing the power of the mobile phone to create a mobile colposcope called EVA COLPO, MobileODT enables women’s health clinicians to perform smart colposcopies and visual assessments at point of care, anywhere in the world.
EVA COLPO is self-contained and portable. It allows consultation with medical experts who might be located remotely from the examination site. The product was approved by the USA Food and Drug Administration (FDA) in 2016.
HPV is responsible for 5% of all cancers worldwide, 99.5% of cervical cancers, and causes oral, throat, anal and genital cancers in both women and men. While HPV is widely believed to be sexually transmitted, studies have demonstrated that the virus also exists on gynaecological equipment. Although EVA COLPO does not directly contact the patient, it is touched by the clinician who has inserted the speculum and is conducting the examination. It is in close vicinity of the woman’s anatomy, therefore at risk of HPV infection and should be disinfected if it easily and affordably can be.
Duo EVE, based on Tristel’s proprietary chlorine dioxide chemistry, is one of the very few disinfectants that is rapidly effective against HPV. It was evaluated in pioneering work by Dr Craig Meyers PhD, Distinguished Professor of Microbiology and Immunology, Penn State College of Medicine, Hershey, USA, and proven to be effective in deactivating HPV 16 and 18 strains in short contact times. HPV 16 and 18 are the virus strains most closely associated with causing cervical cancer. Duo EVE is portable and self-contained, there is no need for water or electricity, it requires no maintenance, and can be used with minimal training.
Tristel and MobileODT have teamed up to protect women around the world with Duo EVE, a mobile, low-cost and high-performance disinfectant that is effective against HPV, and EVA COLPO. The partnership launch was announced at the 32nd International Papillomavirus Conference in Sydney this week (October 2, 2018).
Paul Swinney, Tristel chief executive, says: “Nearly six billion people worldwide have no access to healthcare that we consider to be adequate, but a large percentage of this population does have access to a mobile phone.
“In low-resource areas, either on the African continent or in rural America, medical care is provided by nurses, who are trained to a general level of medical knowledge.
“Smartphones, combined with devices that can illuminate a part of the body and take a picture, or carry out an ultrasound scan, allow community nurses to examine the patient and transmit images for consultation, which can be provided remotely.”
During Tristel’s 25 years of experience in infection prevention, the Company has discovered that disinfection is often an afterthought in medical device development. Its high-performance disinfectants, including Tristel Duo EVE, are dispensed in portable, easy-to-use formats and are the only way in which new devices can be disinfected safely, including in remote areas to the same level that would be expected in a sophisticated hospital.
To find out more information, please contact the Tristel PR team: email@example.com